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Abstract
Proteases, including matrix metalloproteinases (MMPs), tissue serine proteases, and cathepsins (CTS) exhibit numerous functions
in tumor biology. Solid tumors are characterized by changes in protease expression levels by tumor and surrounding tissue. There-
fore, monitoring protease levels in tissue samples and liquid biopsies is a vital strategy for early cancer detection. Water-dispersable
Fe/Fe3O4-core/shell based nanoplatforms for protease detection are capable of detecting protease activity down to sub-femtomolar
limits of detection. They feature one dye (tetrakis(carboxyphenyl)porphyrin (TCPP)) that is tethered to the central nanoparticle by
means of a protease-cleavable consensus sequence and a second dye (Cy 5.5) that is directly linked. Based on the protease activi-
ties of urokinase plasminogen activator (uPA), MMPs 1, 2, 3, 7, 9, and 13, as well as CTS B and L, human breast cancer can be
detected at stage I by means of a simple serum test. By monitoring CTS B and L stage 0 detection may be achieved. This initial
study, comprised of 46 breast cancer patients and 20 apparently healthy human subjects, demonstrates the feasibility of protease-
activity-based liquid biopsies for early cancer diagnosis.
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Figure 2: Mechanistic scheme of the “light switch effect” upon proteolytic cleavage: the fluorophore is switched on due to the increase in distance be-
tween the Fe/Fe3O4 core/shell nanoparticle, leading to decreased Förster resonance energy transfer (FRET) [21,24], k1, and dipole–surface energy
transfer (SET) [20,22], k2. Further explanations are provided in the text.
Introduction
We have detected stage I breast cancer in human patients with
statistical significance by means of a simple serum test using
highly sensitive Fe/Fe3O4-nanoparticle based nanoplatforms for
protease detection. Numerous proteases are required for early
mutations, tumor survival, progression, angiogenesis, and inva-
sion [1-3]. Following the pioneering research of Weissleder et
al. [4], molecular [5], macromolecular [6] and nanoparticle-
based [7] protease sensors have been developed for in vivo
imaging and in vitro diagnostics of proteases that rely on fluo-
rescence and magnetic principles [8]. This technology is charac-
terized by high versatility and specificity, because consensus se-
quences feature high selectivities for the proteases for which
they were designed [9]. However, the limits of protease detec-
tion (LOD’s) of the state-of-the-art technology are sub-pico-
molar (sub-ng/mg) [4-8], which is sufficient for in vivo imaging
of tumors [4,8], atherosclerotic plaques [10] and cardiovascular
inflammation [11] in humans and in vivo and in vitro detection
in rodent models for cancers [12,13], but not for the in vitro
detection of human cancers [14] in their earliest stages.
Competing technologies for quantitative protease detection,
such as immunosorbent assays [15], quantum dot barcode tech-
nology [16], and immunobeads [17] have similar LOD’s.
Recently, Sardar, Korc et al. have reported the sensing of short
noncoding RNA following a nanoplasmonic approach, which is
of similar sensitivity and range as the approach reported here
[18].
We have developed nanoplatforms for protease detection
[19,20] that are capable of detecting protease activities over a
wide activity range down to sub-femtomolar LOD’s. These
nanoplatforms consist of dopamine-covered, water-dispersable
iron/iron oxide core/shell nanoparticles, to which one fluores-
cent dye (TCPP, tetrakis(carboxyphenyl)porphyrin) is tethered
via a consensus sequence. A second dye (cyanine 5.5) is perma-
nently linked to the dopamine coating (Figure 1). This design
enables both, plasmon-resonance quenching (SET) [20,21] and
Förster resonance energy transfer (FRET) quenching [20,22] of
the tethered TCPP units. Once TCPP is released via proteolytic
cleavage of the consensus sequence, its fluorescence will
increase (for most of the nanoplatforms).
Figure 1: Nanosensors for in vitro protease detection. For each
protease, a highly selective oligopeptide is used to tether tetrakis-
carboxy-phenyl-porphyrin (TCPP) to the nanoparticle. Cyanine 5.5 is
linked permanently to the Fe/Fe3O4 nanoparticles. Figure 1 is repro-
duced from [23] with permission.
The nanoplatforms for cancer detection are based on proteo-
lytic cleavage of TCPP from the Fe/Fe3O4-core (Figure 2).
Increasing the distance between the TCPP fluorophore and
the nanoparticle decreases plasmon-resonance quenching
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Figure 3: TEM (1a,1b) and HRTEM (1c) images of Fe/Fe3O4-core/shell nanoparticles that are forming the inorganic core of the nanoplatforms for
protease detection, with permission from [20], copyright 2014 Royal Society of Chemistry. HRTEM images revealed that the Fe(0) centers are mostly
crystalline (BCC).
(dipole–surface energy transfer (SET) [20,21]) from TCPP to
Fe/Fe3O4 and Förster resonance energy transfer (FRET [20,22])
from TCPP to cyanine 5.5. The latter is permanently tethered to
the inorganic nanoparticle. For all of the employed consensus
sequences, with the exceptions of GAGSGR-SAG for uPA and
GAGVPLS-LYSGAG for MMP 9, an increase in TCPP fluores-
cence is observed upon enzymatic cleavage. This “light switch
effect” [20] enables highly sensitive detection of protease activ-
ity by quantitative fluorescence measurements. In an earlier
paper, we have discussed in detail why the nanoplatforms for
uPA and MMP 9 detection defy the general paradigm: shorter
consensus sequences and sequences permitting higher dynam-
ics of the attached TCPP lead to fluorescence enhancement of
the attached fluorophore due to enhanced plasmonic light scat-
tering [24] of the Fe(0) core of the central core/shell nanoparti-
cle. For these specific consensus sequences, this effect exceeds
the quenching effects (SET and FRET). Therefore, these two
nanoplatforms show decreases of TCPP fluorescence upon
cleavage. However, this decrease can still be utilized to measure
the activities of uPA and MMP 9 in serum.
In the US, breast cancer is staged according to the TNM classi-
fication system, which is based on the extent of the spread of
cancer within the body [25]. The overall 5-year survival rates
for breast cancer are virtually 100% at stages 0 and I, 93% at
stage II, 72% at stage III and 22% at stage IV [26]. 61% of all
breast cancers in the US are diagnosed at combined stages 0 and
I, 32% at stage II and 7% at combined stages III and IV [27].
Since the majority of breast cancer mortalities occurs from
cases that are detected at stages II and above, detecting breast
cancer by means of a routine blood test at stage I or earlier
would have the potential of significantly reducing breast cancer
mortality (521,900 globally in 2012) [28].
Bhatia et al. proposed nanoscale agents for in vivo use that are
comprised of reporter molecules bound via consensus se-
quences to iron oxide nanoworms. The reporter molecules are
released in rodent models once the nanoworms have reached the
cancer site and then excreted in urine. The quantitative detec-
tion of the reporter molecules’ concentrations has been achieved
by paper chromatography [29]. Although this was a major step
forward in developing point-of-care diagnostics, it is still more
than minimally invasive, because the nanoworms have to be
given intravenously. An ideal “liquid biopsy” [30] will require
only the drawing of a simple blood sample to detect cancer,
without introducing a reagent to the patient’s body first. In this
report, we would like to discuss this approach.
In 2014, we published the synthesis and calibration of
Fe/Fe3O4-based nanoplatforms for accurate and highly sensi-
tive detection of 12 proteases (Figure 1) [20]. The calibration
and validation experiments were performed with commercially
available proteases in PBS (phosphate buffered saline, pH 7.4).
The average Fe(0) core diameter is 13 ± 0.5 nm, the Fe3O4 shell
thickness is 2.0 ± 0.5 nm (Figure 3). Using statistical modeling,
the optimal number of TCPP units per nanoparticle was deter-
mined to be 35 ± 3, and the number of cyanine 5.5 units to be
50 ± 4 [31].
We have obtained serum samples (−80 °C) from 46 female
breast cancer patients (4 stage 0, 9 stage I, 9 stage II, 12 stage
III and 12 stage IV, as well as 20 healthy human subjects
(10 males and 10 females)) from the Southeastern Nebraska
Cancer Center. We have selected serum as biospecimen,
because at −80 °C protease activity is retained for years accord-
ing to our preliminary results. 20 breast cancers were luminal A
[32], 12 were luminal B [33], 8 were basal-like [32] and 6 were
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Figure 4: Matrix effects for MMP7, MMP13, and cathepsin L after 60 min of incubation at 25 °C under standard conditions. Ip: fluorescence signal
after 60 min of incubation; Ic: fluorescence signal in the absence of protease after 60 min incubation; Is: fluorescence signal of serum/PBS-dextran
alone. Experimental errors are indicated.
HER2 enriched [32]. All patients (ages 36 to 80) and healthy
human subjects (ages 26 to 68) were Caucasian. No significant
statistical differences in the protease expression pattern be-
tween the females and males of the control group were found.
Approx. two percent of the human genome encodes for
proteases [34]. Therefore, each selection of proteases for a
cancer diagnostic panel is somewhat arbitrary. For detecting
early breast cancer, we have chosen the following proteases:
MMPs 1, 2, 3, 7, 9, 13, uPA and CTS B and L. MMP 1 has
been associated with telomerase activity and promotion of
tumor invasiveness and metastatic dissemination [35]. MMPs 2,
7, and 9, as well as other MMPs, release growth factors from
stromal and epithelial cells at the cancer boundary, cleave off
pro-angiogenic factors and start pro-angiogenic protease
cascades [36,37]. MMP 13 is involved in the epithelial-mesen-
chymal transition [38]. uPA and CTS B facilitate angiogenesis,
ECM degradation and invasiveness. They also activate growth
factors [39,40]. MMP3 and CTS L are responsible for early
mutations in carcinogenesis [2,3].
Results and Discussion
In step 1, the influence of the serum matrix on the performance
of the nanoplatforms was evaluated. For this purpose, we have
used combined serum from our control group, which was inacti-
vated using established procedures by heating to 56 °C for
>30 min [41].
In short, 3.0 mL of dextran (10 mg dextran in 1.0 mL of PBS)
were mixed with 75 µL of the nanoplatform dispersion (1.0 mg
in 1.0 mL of PBS) and 30 µL of the protease stock solutions at
each concentration level in a total volume of 3.0 mL of PBS.
30 µL of inactivated serum was added before filling up to
3.0 mL when studying matrix effects. The solution was incubat-
ed at 25 °C for 60 min. Then the fluorescence was analyzed in
4.0 mL quartz-cuvettes (Helma) using a spectrofluorometer
(Fluoromax2) with dual monochromators (λex = 421 nm, λem =
620–680 nm). The complete procedure is described in the
Methods section. From 10 independently performed repetitions,
we have calculated the experimental error to ±3% (Supporting
Information File 1, Figure S3).
The results obtained in the presence and absence of inactivated
serum are shown in Figure 4 and Figure 5, as well as Figure S1
in Supporting Information File 1 (Triangles: fluorescence read-
ings in PBS; Squares: fluorescence readings in PBS containing
inactivated serum.) Most proteases only exhibit moderate
matrix effects, because of the very low concentration of serum
that is required and due to the use of dextran as anticoagulant
[42]. The requirement of only a very low volume of serum for
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Figure 5: Matrix effects for MMP1, MMP 2, MMP 3, and cathepsin B after 60 min of incubation at 25 °C under standard conditions. Triangles: fluores-
cence readings in PBS; Squares: fluorescence readings in PBS containing inactivated serum. Ip: fluorescence signal after 60 min of incubation; Ic:
fluorescence signal in the absence of protease after 60 min incubation; Is: fluorescence signal of serum/PBS-dextran alone. Experimental errors are
indicated.
performing meaningful enzyme activity measurements is a defi-
nite advantage of the very high sensitivity of the nanoplatforms
for protease detection, which originates from the concurrent
utilization of SEM and FRET quenching.
Notable exceptions are MMPs 1 (Figure 5) and 7 (Figure 4)
where significant matrix effects were detected. As noted in Ta-
ble S1 in Supporting Information File 1, the physical properties
(isoelectric point and hydrophobicity index) of the consensus
sequences plus peptide linkers designed for detecting MMP 1
and MMP 7 are within the ranges defined by all employed
peptide sequences. Pieper et al. have analyzed human serum by
fractionating serum proteins, followed by two-dimensional elec-
trophoresis, and sequential anion-exchange and size-exclusion
chromatography. They have resolved 3700 posttranslationally
modified proteins [43]. Based on their findings, we cannot
exclude that binding of the peptide sequences designed for
MMP 1 and MMP 7 detection to one or several serum protein
occurs, which is ultimately responsible for the observed photo-
physical behavior of these nanoplatforms.
In Supporting Information File 1, Figure S1 the results for uPA
and MMP9, two proteases that defy the “light switch paradigm”
are shown. An explanation for this behavior is briefly discussed
in the Introduction section and more thoroughly in [20].
Cross-sensitivities of the nanoplatforms
In order to determine the cross-sensitivities of the nanoplat-
forms, the following control experiments were conducted:
The nanoplatforms for MMP 1, 2, 3, 7, 9, 13, uPA, and CTS B,
L were (separately) incubated with 1.0 × 10−10 mol L−1 of
MMP 1 under standard conditions (see Methods). After 60 min
of incubation at 25 °C, the fluorescence spectra of all
nanoplatforms were recorded. The next set of experiments con-
sisted of incubating the nanoplatforms for MMP 1, 2, 3, 7, 9,
13, uPA, and CTS B, L with 1.0 × 10−10 mol L−1 of MMP 2
under standard conditions. This is followed by MMP 3, 7,
9, 19, uPA and CTS B, and L. In Figure 6, the normalized
results for this set of experiments are summarized. The normal-
ization procedure consists of dividing each set of integrated
fluorescence data for each enzyme by the fluorescence
recording for the correct match in the entire set of nine
nanoplatforms.
Set 1: integrated fluorescence recordings for all nine nanoplat-
forms incubated with MMP 1 (1.0 × 10−10 mol L−1), divided by
the integrated fluorescence signal obtained with the nanoplat-
form for MMP 1 in the presence of MMP 1.
Set 2: integrated fluorescence recordings for all nine nanoplat-
forms incubated with MMP 2 (1.0 × 10−10 mol L−1), divided by
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Figure 6: Cross-sensitivities of the nanoplatforms used in this study. Further explanations are provided above.
Figure 7: Bar graph (left, showing means and standard deviations) and box plot (right, indicating the observed data range) for cathepsin L. The group
sizes are H (apparently healthy control group, n = 20), 0: breast cancer stage 0 (n = 4), 1: breast cancer stage 1 (n = 9), 2: breast cancer stage 2
(n = 9), 3: breast cancer stage 3 (n = 12); 4: breast cancer stage 4 (n = 12). All biospecimens were obtained from the South Eastern Nebraska Cancer
Center (SNCC). Breast cancer has been staged according to the TNM staging system [25].
the integrated fluorescence signal obtained with the nanoplat-
form for MMP 2 in the presence of MMP 2.
Sets 3 to 8 have been recorded accordingly for MMP 3, 7, 9, 13,
uPA and CTS B.
Set 9: integrated fluorescence recordings for all nine nanoplat-
forms incubated with CTS L (1.0 × 10−10 mol L−1), divided by
the integrated fluorescence signal obtained with the nanoplat-
form for CTS L in the presence of CTS L.
Diagnosis of early breast cancer
The activities of the nine selected proteases in the serum of 46
breast cancer patients and 20 healthy human subjects were
measured following the same procedure as for determining the
matrix influence, with the exception that active serum was used,
and the results statistically analyzed. A series of boxplots and
bar graphs (Figure 7 and Supporting Information File 1, Figures
S4–S12) show the data range that correlates to each cancer
stage, as well as the protease expression range of healthy
patients [44].
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Figure 8: Calculated p-values; comparison of breast cancer patients and healthy human subjects for all investigated enzymes, stages 0–4. Green:
fluorescence signal (FS) of cancer patients is significantly larger than of control group (CG); Yellow: FS is significantly smaller; Red: differences in FS
and CG are not significant.
The analyzed enzymes include cathepsin B and L, MMP 1, 2, 3,
7, 9, 13 and uPA. Except for MMP9 and uPA, all enzymes
display a positive trend with an increasing signal for higher
cancer stages. The reason for this behavior is discussed in the
text: in short, the nanoplatforms for uPA and MMP 9 detection
show decreasing fluorescence intensities with increasing
protease activity. We have chosen boxplots and bar graphs for
data analysis, in combination with Welch two sample t-tests
(control group and cancer patients at a defined stage) [45],
because a combination of these analysis methods provides a
simple system for data analysis. The boxplots show the data
range that correlates to a certain cancer stage while the bar
graphs display the average signal and standard deviation (repre-
sented by the error bar) for individual cancer stages.
With respect to detecting cancer at an early stage, the data ob-
tained for cathepsin B and L, uPA and MMP 1, 3 and 9 is supe-
rior to MMP 2, 7 and 13. Here the fluorescence signals for each
cancer stage are compared with the healthy control group’s
fluorescence signals. Highly significant differences between
cancer patients and healthy control group are achieved with
cathepsin B and L, uPA, MMP1 and 9. It is noteworthy that
only cathepsins B and L are significantly different from the
healthy group for stage 0 breast cancer. Especially cathepsin L
seems promising here since it maintains its positive trend of the
signal. However, the stage 0 group is very small (n = 4). There-
fore, all enzymes should be revisited when more data becomes
available.
Highly significant differences are achieved with CTS B, L,
uPA, MMP 1 and 9. It is interesting to observe that only CTS B
and L produce a signal for stage 0 breast cancer that is signifi-
cantly different from the healthy group. Especially CTS L
seems promising here since it maintains its positive trend of the
signal. However, the stage 0 group is too small (n = 4) and the
control group is somewhat spread out. Stage 0 must be revis-
ited when more data becomes available.
In Figure 8, the calculated p-values [45] obtained for compari-
sons of the protease expression pattern in each cancer stage with
those of the healthy control group are tabulated, leading to the
“Significance Table”. The color green denotes for measured
fluorescence signals that are significantly enhanced (p < 0.05)
in cancer patients compared to the healthy control group. The
color yellow represents findings, in which the fluorescence
signals detected in the serum of cancer patients were signifi-
cantly smaller than in the control group. The color red was used
for all cases in which significant results could not be obtained.
It should be noted (again) that uPA and MMP 9 are the “defiant
proteases”. Their fluorescence signals decrease with increased
protease activity.
The resulting average enzyme activities in the serum of the
healthy control group and breast cancer stages 0, 1, 2, 3, and 4
are summarized in Figure 9. Healthy control groups and stages
are color coded. From this plot, it can be discerned why
cathepsin L is the best enzyme to detect both, early breast
cancer and cancer staging. MMP 1, MMP 9 and uPA show sim-
ilar enzyme activity trends, but we were unable to distinguish
between healthy patients and stage 0 breast cancer patients. The
inability to reach this goal was due to variations of protease
expression among the apparently healthy human subjects and
the small sample size (n = 4) in stage 0. Cathepsin B, MMP 2
can be used to identify breast cancer patients that are in or
beyond stage 2. MMP 3 could, in theory, identify late stage
patients. Finally, MMP 7 and MMP 13 did not yield conclusive
results. It is noteworthy that although MMP 2, 7, and 9 belong
to a group of MMPs that are known to release growth factors,
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Figure 9: Average protease activity as a function of breast cancer stage/healthy control group for all nine proteases monitored in this study. Note that
the activity is shown on a logarithmic scale (log10 (protease activity)). The data summarized in this figure is also reported in Supporting Information
File 1, Tables S1–S9.
cleave off pro-angiogenic factors and start pro-angiogenic
protease cascades [36,37], MMP 2 and MMP 9 yield conclu-
sive results for stages one to four, whereas MMP 7 is only
conclusive at higher stages. MMP 13 did not generate any sig-
nificant results, although MMP 13 is involved in the epithelial-
mesenchymal transition [38]. The reasons for these deviations
among related matrix metalloproteinases may be found in dif-
ferent tissue retention and enzymatic degradation of individual
proteases, as well as in the activity profiles of tissue inhibitors
of metalloproteinases (TIMPs) in blood [46].
In conclusion, the most important result of this research is that
we are able to detect breast cancer at stage I monitoring seven
proteases and at stage 0 observing one protease with high statis-
tical significance. This result is of importance, because we have
achieved it with relatively small group sizes of breast cancer
patients and healthy control subjects. As always when testing
biomarkers, the selection process of the required biospecimens
is crucial. Therefore, our next steps will consist in testing our
liquid biopsy approach with significantly larger group sizes of
stage 0 and I breast cancer patients.
Methods
Nanoplatform synthesis
The synthesis and characterization of the nanoplatforms for
protease detection is described in detail in [19]. In short, water-
dispersible Fe/Fe3O4 nanoparticles featuring dopamine ligands
[47], TCPP [48], and cyanine 5.5 [49] were synthesized accord-
ing to established procedures. The oligopeptides used as
consensus sequences, which were synthesized in the Bossmann
group by means of solid-supported peptide synthesis [20], are
summarized in Table 1. TCPP was connected to the N-terminal
end of the oligopeptides while it was still on the resin. The
TCPP-oligopeptide was then cleaved off the resin and linked to
the primary amine groups of Fe/Fe3O4 bound via an amide
bond [20]. Note that these sequences also contain GAG and AG
as peptide linkers.
Standard procedure of preparing protease
assays (without serum)
3.0 mg of nanoplatform were dissolved in 3.0 mL of PBS. The
dispersion was sonicated for 10 min. The resulting dispersion is
chemically stable for 14 days at 4 °C. 900 mg of dextran were
dissolved in 90 mL of PBS. Stock solutions of all 9 enzymes
were prepared by consecutive dilution of commercially avail-
able proteases (Enzo Lifesciences). 3 mL of PBS–dextran
(10 mg dextran in 1.0 mL of PBS) are mixed with 75 µL of the
nanoplatform dispersion (3.0 mg in 3.0 mL of PBS, see above)
and 30 µL of each of the proteases at every concentration level
in PBS. The dispersions were incubated at 25 °C for 60 min,
followed by the recording of a fluorescence spectrum at
25 °C using a Fluoromax2 spectrometer (λem = 421 nm, λex =
620–680 nm).
Standard procedure of preparing protease
assays (with inactivated serum)
3.0 mg of nanoplatform were dissolved in 3.0 mL of PBS. The
dispersion was sonicated for 10 min. The resulting dispersion is
chemically stable for 14 days at 277 K. 900 mg of dextran were
dissolved in 90 mL of PBS. Stock solutions of all 9 enzymes
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Table 1: Consensus sequences in single-letter code for 9 proteases (http://www.lifetein.com/peptide-analysis-tool.html). Essential amino acids of the
consensus sequences are bold.
Protease Consensus sequence Isoelectric point (pI) Hydrophobicity index at pH 6.8
MMP1 GAGVPMS-MRGGAG 11.18 18.54
MMP2 GAGIPVS-LRSGAG 11.18 22.08
MMP3 GAGRPFS-MIMGAG 11.18 27.77
MMP7 GAGVPLS-LTMGAG 6.09 30.31
MMP9 GAGVPLS-LYSGAG 6.0 28.08
MMP13 GAGPQGLA-GQRGIVAG 11.18 19.88
uPA GAGSGR-SAG 11.18 22.08
Cathepsin (CTS) B GAGSLLKSR-MVPNFNAG 11.6 20.82
Cathepsin (CTS) L GAGSGVVIA-TVIVITAG 6.09 43.82
were prepared by consecutive dilution of commercially avail-
able proteases (Enzo Lifesciences). 3 mL of PBS–dextran
(10 mg dextran in 1.0 mL of PBS) are mixed with 75 µL of the
nanoplatform dispersion (3.0 mg in 3.0 mL of PBS, see above),
30 µL of inactivated serum, and 30 µL of each of the proteases
at every concentration level in PBS. The dispersions were incu-
bated at 25 °C for 60 min, followed by the recording of a fluo-
rescence spectrum at 25 °C using a Fluoromax2 spectrometer
(λex = 421 nm, λem= 620–680 nm). Inactivation of serum was
achieved by heating to 56 °C in an incubator for 45 min, taking
the heating time of the serum from RT to the chosen tempera-
ture into account, making sure that the serum is heated for a
minimum of 30 min. Inactivated serum tested negative with all
nine nanoplatforms for protease measurements employed in this
study.
Supporting Information
Supporting Information File 1
Determination of matrix effects on the observed
fluorescence intensities of the nanoplatforms, relative error
from 10 repetitive protease measurements, and comparison
of cancer stages and boxplots for each of the investigated
proteases.
[http://www.beilstein-journals.org/bjnano/content/
supplementary/2190-4286-7-33-S1.pdf]
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